Breaking News

Bamboo Therapeutics Acquires Manufacturing Facility

January 15, 2016

UNC-Chapel Hill Vector Core is a leading manufacturer of viral gene therapies

Bamboo Therapeutics, a biotechnology company focused on developing gene therapies for rare neurological diseases, has acquired the viral gene therapy manufacturing facility—Vector Core—from the University of North Carolina (UNC) at Chapel Hill, NC. Financial Details were not disclosed.

The Vector Core was founded in 1993 as a full-service viral vector production organization with extensive experience in vector design and process development, as well as manufacturing of research and clinical grade vectors. This 11,000 square foot facility has produced multiple research grade and clinical grade lots for pharmaceutical and biotechnology companies, as well as universities and foundations.

Bamboo has developed a proprietary suspension cell-based production platform that utilizes serum-free/chemically defined media to increase scalability, efficiency and purity. The proprietary system is designed to decrease the amount of processing steps necessary in methods using adherent cells, while also reducing the variability and shortcomings associated with using animal serum.

“We believe that having a leading manufacturing facility fully integrated into our business provides flexibility and a competitive advantage,” said Jude Samulski, scientific founder and chairman, Bamboo Therapeutics. “We anticipate rapidly moving our programs forward, including our DMD program, which is expected to enter the clinic in early 2017.”

Related Contract Manufacturing:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks